



Research Publication Repository

<http://publications.wehi.edu.au/search/SearchPublications>

This is the author's peer reviewed manuscript version of a work accepted for publication.

Publication details:	Jacobsen AV, Murphy JM. The secret life of kinases: insights into non-catalytic signalling functions from pseudokinases. <i>Biochemical Society Transactions</i> . 2017 45(3):665-681.
Published version is available at:	https://doi.org/10.1042/BST20160331

Changes introduced as a result of publishing processes such as copy-editing and formatting may not be reflected in this manuscript.

The secret life of kinases: insights into non-catalytic signalling functions from pseudokinases

Annette V. Jacobsen^{1,2} and James M. Murphy^{1,2*}

¹ Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia

² Department of Medical Biology, University of Melbourne, Parkville, Victoria 3052, Australia.

*Correspondence to James Murphy (jamesm@wehi.edu.au)

Abstract

Over the past decade, our understanding of the mechanisms by which pseudokinases, which comprise ~10% of the human and mouse kinomes, mediate signal transduction function has advanced rapidly with increasing structural, biochemical, cellular and genetic studies. Pseudokinases are the catalytically-defective counterparts of conventional, active protein kinases, and have been attributed functions as protein interaction domains acting variously as allosteric modulators of conventional protein kinases and other enzymes, regulators of protein trafficking or localisation, as hubs to nucleate assembly of signalling complexes, and as transmembrane effectors of such functions. Here, by categorizing mammalian pseudokinases based on their known functions we illustrate the mechanistic diversity among these proteins, which can be viewed as a window into understanding the non-catalytic functions that can be exerted by conventional protein kinases.

Abbreviations

BUB1B: BUB1 mitotic checkpoint serine/threonine kinase B (also known as BUBR1)
CAB39: calcium binding protein 39 (also known as MO25)
CaMKII: calcium/calmodulin dependent protein kinase II
CAMKV: CaM kinase like vesicle associated (also known as VACAMKL)
CASK: calcium/calmodulin dependent serine protein kinase
CEP55: centrosomal protein 55
CXorf36: chromosome X open reading frame 36 (also known as DIA1R)
EIF2AK4: eukaryotic translation initiation factor 2 alpha kinase 4 (also known as GCN2)
ERBB3: erb-b2 receptor tyrosine kinase 3 (also known as HER3)
FAM20A: FAM20A, Golgi associated secretory pathway pseudokinase
GSK3: glycogen synthase kinase 3
GUCY2C: guanylate cyclase 2C (also known as HSER)
GUCY2D: guanylate cyclase 2D (also known as CYGD)
GUCY2F: guanylate cyclase 2D (also known as CYGF)
IL-1: interleukin 1
ILK: integrin linked kinase
IRAK: interleukin 1 receptor associated kinase
JAK: Janus kinase
KSR: kinase suppressor of ras
MLKL: mixed lineage kinase domain-like
NDPK: nucleoside diphosphate kinase
NF-κB: nuclear factor kappa B
NME: NME/NM23 family member
NPR1: natriuretic peptide receptor 1 (also known as ANPa)
NPR2: natriuretic peptide receptor 1 (also known as ANPb)
NRBP: nuclear receptor binding protein

PAN3: PAN3 poly(A) specific ribonuclease subunit
PEAK1: pseudopodium enriched atypical kinase 1 (also known as SgK269)
PKB: protein kinase B (also known as AKT)
PRAG1: PEAK1 related kinase activating pseudokinase 1 (also known as SgK223 or Pragmin)
PSKH2: protein serine kinase H2
PTK7: protein tyrosine kinase 7 (also known as CCK4)
PXX: PX domain containing serine/threonine kinase like (also known as Slob)
RGC: receptor guanylyl cyclase
RNaseL: ribonuclease L
ROR: receptor tyrosine kinase like orphan receptor
RPS6KC1: ribosomal protein S6 kinase C1 (also known as RPK118 or RSKL1)
RPS6KL1: ribosomal protein S6 kinase like 1 (also known as RSKL2)
RP2: retinitis pigmentosa 2
RYK: receptor-like tyrosine kinase
SCYL: SCY1 like pseudokinase
SELENOO: selenoprotein O (also known as SELO)
SH2: Src homology 2
STKLD1: serine/threonine kinase like domain containing 1 (also known as SgK071)
STK11: serine/threonine kinase 11 (also known as LKB1)
STK31: serine/threonine kinase 31 (also known as SgK396)
STK40: serine/threonine kinase 40
STRAD: STE20-related kinase adaptor
STYK1: serine/threonine/tyrosine kinase 1 (also known as NOK or SuRTK106)
TBCK: TBC1 domain containing kinase
TEX14: testis expressed 14 (also known as SgK307)
TGF- β : transforming growth factor β
TLR: Toll-like receptor
TRIB: Tribbles pseudokinase
TRRAP: transformation/transcription domain associated protein
TTN: titin
TYK2: tyrosine kinase 2
ULK4: unc-51 like kinase 4
VRK3: vaccinia related kinase 3

Introduction

Counterparts of active enzymes that lack key catalytic residues, and are therefore predicted to possess defective catalytic activities, termed pseudoenzymes, are thought to comprise ~10% of proteomes throughout the kingdoms of life [1,2]. Much of the recent interest in these proteins has originated from studies of the catalytically-defective cousins of kinases, called pseudokinases [3], however much remains unknown about pseudokinase function. Nonetheless, detailed studies of pseudokinases indicate they serve functions in cell signalling as protein interaction modules that can allosterically regulate the activities of conventional protein kinases or other enzymes; regulate trafficking or cellular localisation of other proteins; and nucleate assembly of signalling complexes. As a result, it has become clear that these proteins are not merely bystanders in cell signalling, but rather perform crucial regulatory functions. Furthermore, development of small molecules that modulate pseudokinase signalling functions may represent a novel avenue for therapeutic intervention in human diseases, including cancers [4].

With the growing interest in pseudokinase function, different approaches have emerged to group these proteins into different classes. Initially, pseudokinases were identified on the basis of deviations from the conventional Hanks *et al.* [5] VAIK, HRD and DFG catalytic motifs [6], corresponding to the ATP-positioning Lys, YAMK⁷², catalytic loop Asp, YRD¹⁶⁶, and Mg²⁺ binding Asp, D¹⁸⁴FG, motifs in the archetypal kinase, PKA [7]. Subsequently Boudeau *et al.* [8] categorised pseudokinases into groups based on the catalytic motif(s) absent from their sequences. Subsequent classifications have focused on pseudokinase function, such as capacity to bind nucleotides, divalent cations, and nucleotides in the presence of divalent cations [9]. While the role of nucleotide binding in pseudokinase function remains an open question, an absence of detectable ATP binding would be incompatible with a pseudokinase exhibiting phosphoryl transfer catalytic activity. Such a functional analysis lends itself to consideration of kinase-like domains, like those of receptor tyrosine kinase like orphan receptor (ROR)1, ROR2, receptor-like tyrosine kinase (RYK) and BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B/BUBR1) that, based on the presence of conventional Hanks motifs, would be predicted to exhibit nucleotide binding, but experimentally fail to bind [9,10]. Surprisingly, the survey of nucleotide binding by 31 pseudokinases revealed that less than half were capable of nucleotide binding [9], supporting the notion that pseudokinases have evolved functions as protein interaction domains distinct from catalytic activities. From this perspective, we can use insights into protein interactions mediated by pseudokinases to explore the secret lives of conventional protein kinases as protein interaction modules [11]. Here, we have aimed to further classify mammalian pseudokinases based on their functions in cell signalling deduced by recent biophysical, biochemical, cellular and genetic studies.

Pseudokinases as allosteric modulators of enzymatic activities

As part of the process of switching between an inactive and active state, protein kinases undergo dynamic structural changes typified by the assembly of hydrophobic regulatory (R-) and catalytic (C-) spines [12]. This ability to sample different conformations equips kinase (and kinase-like) domains to function allosterically to modulate the activity of other enzymes, and in particular other protein kinases. Due to their catalytic deficiencies, pseudokinases have emerged as useful models to study the non-catalytic, allosteric properties of kinases in isolation. A number of pseudokinases allosterically influence activity of kinase domains within the same protein or within complexes with proteins (**Figure 1**). In addition, there are examples of pseudokinases modulating other classes of enzymes. In the latter class, this includes vaccinia related kinase 3 (VRK3), which binds to and allosterically regulates the Erk phosphatase DUSP3/VHR [13–15], and PAN3 poly(A) specific

ribonuclease subunit (PAN3), which associates with the deadenylase PAN2 and is responsible for both promoting PAN2 catalytic activity and the recruitment of mRNA to the complex [16–19].

The Janus kinase (JAK) family are a well-studied example of pseudokinase modulation of a kinase domain within the same protein. JAKs are non-receptor tyrosine kinases involved in signalling downstream of cytokine receptors, and contain pseudokinase and canonical tyrosine kinase domains in tandem (reviewed in [20]). Although the JAK2 pseudokinase domain has been reported to possess residual catalytic activity [21], the main function of this domain in all JAK family members is to associate with, and negatively regulate, the kinase domain. The tyrosine kinase domain of all JAKs displays constitutive activity when expressed independently, and this is suppressed on co-expression with the pseudokinase domain, either independently or in tandem [22–25]. Deletion of the pseudokinase domain alone leads to constitutive activity of the adjacent tyrosine kinase domain in JAK2 [23], suppression of kinase activity in tyrosine kinase 2 (TYK2) [26], with contradictory reports in JAK3 [24,27], however in all these cases there is a loss of responsiveness to upstream cytokine signalling. Similarly, impacts of disease-associated mutations within the pseudokinase domain of JAK family members are varied, with mutations causing activation of the tyrosine kinase domain common in haematological malignancies (reviewed in [28]), and loss of function mutations presenting in immune deficiencies (reviewed in [29]). The only multi-domain structure for the JAK pseudokinase-kinase tandem domains is for TYK2, which shows multiple interfaces between the N lobes and linker region of the two domains, ‘locking’ the kinase domain and preventing its activity, supporting an inhibitory mechanism [22]. While possible this mechanism is conserved throughout the JAK family, an alternative idea has been proposed where the JAK1 and JAK2 pseudokinase domains might inhibit the activity of the tyrosine kinase domain from a receptor-associated JAK dimer *in trans* [30–32]. Despite being heavily studied, the exact mechanism by which the JAK pseudokinase domains suppress the activity of the tyrosine kinase domain remains an open question. Another protein that contains a tandem kinase and pseudokinase domain is eukaryotic translation initiation factor 2 alpha kinase 4 (EIF2AK4/GCN2), whose primary function is as a negative regulator of translation during amino acid starvation (reviewed in [33]). In contrast to the JAKs, the pseudokinase domain of GCN2 positively regulates activity of the kinase domain, and is required for its catalytic activity, with mutation of conserved residues in the pseudokinase domain abrogating kinase function [34].

The STE20-related kinase adaptor (STRAD) pseudokinases allosterically regulate the kinase domain of a different protein. Both STRADA and STRADB bind to serine/threonine kinase 11 (LKB1/STK11), a key upstream regulator in AMPK signalling, with the assistance of the scaffold protein calcium binding protein 39 (MO25/CAB39) [35–37]. The structure for the heterotrimeric complex of STRADA-LKB1-MO25 has been determined and shows multiple interactions between all three proteins that promote an active conformation of LKB1, including direct associations of the substrate binding site and pseudoactivation loop of STRADA with the LKB1 kinase domain [38]. Calcium/calmodulin dependent serine protein kinase (CASK), which acts as a scaffold for synaptic membrane proteins and ion channels and is proposed to have limited catalytic activity under cation-free conditions [39], associates with the regulatory region of calcium/calmodulin dependent protein kinase II (CaMKII) and promotes inhibitory autophosphorylation of CaMKII in Ca^{2+} /CaM free conditions [40–42]. CASK also associates with CaMKII in the presence of Ca^{2+} /CaM, allowing it phosphorylate substrates, but with lower efficiency than unbound CaMKII [40]. Last is the recently described FAM20A, Golgi associated secretory pathway pseudokinase (FAM20A), a secretory protein that forms heterotetrameric complexes with the active kinase FAM20C [43,44]. This interaction promotes stability and secretion of FAM20C, and increases FAM20C kinase activity in a manner consistent with allosteric regulation [43,45].

Transmembrane pseudokinases

Nearly a quarter of known pseudokinases contain a transmembrane domain, and act as receptors themselves or modulators of membrane receptor function (**Figure 2**). Of these, the largest sub-group are the receptor guanylyl cyclases (RGCs), whose pseudokinase domain sits in the cytoplasmic portion between their transmembrane domain and a functional guanylyl cyclase domain (reviewed in [46]). The RGCs all form homodimers and, upon ligand stimulation, the association of the pseudokinase domains enables activation of the guanylyl cyclase domains through a proposed allosteric mechanism (reviewed in [47]). The pseudokinase domains of this receptor family also bind ATP, which has been found to be important for their function [48–51].

The RGCs all have a similar basic function, which is to restore cellular levels of cGMP, however the stimulus that initiates this varies. Natriuretic peptide receptor 1 and 2 (NPR1; NPR2) are both receptors for natriuretic peptide hormones, and are involved in cellular processes such as control of blood pressure and heart function [52–54]. Guanylate cyclase 2C (GUCY2C/HSER) is preferentially expressed in the gut, and the most well described ligand an *Escherichia coli* enterotoxin (reviewed in [55]). The two retinal specific RGCs, guanylate cyclase 2D and 2E (GUCY2D; GUCY2F), have no known extracellular ligand and instead are stimulated by the binding of activating proteins to the pseudokinase domain [56–58]. Interestingly, chimeric proteins in which the pseudokinase domains of GUCY2D and GUCY2F were swapped retained the characteristics of the originating pseudokinase domains, highlighting its importance for both protein activity and specificity [56].

The next sub-group of pseudokinases respond to the binding of Wnt ligands. This includes ROR1 and the better-studied ROR2, which both bind the non-canonical Wnt ligand Wnt5a [59,60], with ROR2 also known to bind other canonical and non-canonical Wnt ligands [61]. While these proteins are unlikely to possess catalytic activity because they do not detectably bind nucleotides [9], they function in Wnt signalling act as scaffolds to recruit other interacting partners, including Src and glycogen synthase kinase 3 (GSK3) [62–64]. ROR2 is known to form homodimers or heterodimers with ROR1 as well as associating with Fzd receptors and inducing their internalisation [60,65]. ROR1 is predominantly expressed during development, and is proposed to function as a signalling hub by associating with various receptor tyrosine kinases (RTKs) [66,67] and as the switch between pro-apoptotic p38 signalling and pro-survival Src dependent PKB/AKT activation [68].

The pseudokinase RYK is another important Wnt5a binding protein, and RYK knockout mice have many phenotypic similarities to Wnt5a knockout mice [69–72]. In addition, RYK can bind other Wnt ligands and has a role in Wnt induced neural outgrowth [73,74]. Another Wnt receptor is protein tyrosine kinase 7 (PTK7/CCK4), a Wnt4 co-receptor that promotes non-canonical Wnt signalling by binding Dishevelled and receptor for activated C kinase 1 (RACK1) through an interaction with the pseudokinase domain [75–77]. In addition, the pseudokinase domain acts as a scaffold to bind and stabilise β -catenin in the absence of canonical Wnt signalling [78]. Although it does not contain an ectodomain, the membrane-bound pseudokinase, serine/threonine/tyrosine kinase 1 (STYK1/NOK/SuRTK106), acts as a scaffold to promote the phosphorylation of GSK3- β , an important Wnt kinase, as well as interacting with and promoting phosphorylation of PKB/AKT and modulating MAPK signalling pathways [79,80]. It is proposed that STYK1 influences both of these pathways by enabling the interaction of these kinases with upstream PI3Ks [79].

The remaining membrane pseudokinases are proposed to influence receptor signalling through their interaction with transmembrane kinases of the same family. Erb-b2 receptor tyrosine kinase 3

(ERBB3/HER3) is a well-studied pseudokinase long known to form homodimers, as well as heterodimers with other EGFR/ErbB family members [81–83]. In heterodimers, ERBB3/HER3 allosterically activates the partner kinase to enable downstream signalling through stabilisation of the N-lobe of the active kinase by interaction with the ERBB3/HER3 C-lobe [84–86]. Although ERBB3/HER3 has been found to possess residual catalytic activity [87], mutations that ablate this do not affect signalling (reviewed in [88]), implying its kinase activity has limited biological relevance. Moreover, active kinases within the HER3/ErbB3 family have also been shown to allosterically regulate other family members and themselves [86]. The idea that a pseudokinase or conventional kinase can equally function as an allosteric modulator (“activator”) of a “receiver” kinase’s activity is highly illustrative of the lessons one can learn about allostery among conventional kinases from detailed studies of the pseudokinases. Finally, there are two pseudokinase members in the Eph family of receptors: Eph receptor B6 (EPHB6) and EPHA10. Although little is known about the function of EPHA10, EPHB6 can form heterodimers with, and is phosphorylated by, a number of other Eph receptors, and acts as a negative regulator of JNK signalling [89–92]. Additionally, EPHB6 strongly associates with the Src family kinase Fyn, as well as the oncogenic E3 ligase c-Cbl [89,90,92].

Pseudokinase signalling hubs

In addition to the JAK kinase family, there are a number of other cytoplasmic pseudokinases that are integral for modulating signals through receptor complexes (**Figure 3**). The kinase suppressor of Ras 1 and 2 (KSR1/2) proteins are excellent examples of this, and are able to act as inducers or inhibitors of Ras/MAPK signalling, depending on cellular context and KSR expression levels [93,94]. They act downstream of multiple RTKs and, although there has been some debate over whether they possess catalytic activity [95–97], their most well studied role is as a scaffold to mediate interactions between MEK and Raf kinases [97–100]. Raf kinases, like the EGFR/ErbB family of kinases, also form homo- and hetero- dimeric units, where one partner acts as a non-catalytic activator of the partner protein’s kinase activity. In this case, both the conventional protein kinase, Raf, and the catalytically-defective, KSR1, can heterodimerise with Raf proteins to promote their kinase activity [101,102], again asserting that non-catalytic functions (the “secret lives”) of conventional enzymes can be revealed by detailed studies of their dead counterparts. Both KSR1 and KSR2 have multiple documented interacting partners and form large protein complexes stabilised by a number of chaperone proteins [103,104].

Signalling through nuclear factor kappa B (NF- κ B) downstream of Toll-like receptor (TLR) ligands, interleukin 1 (IL-1) and transforming growth factor β (TGF- β) is controlled by the interleukin 1 receptor associated kinase (IRAK) family (reviewed in [105]). Although IRAK1 and IRAK4 are conventional (active) protein kinases, both IRAK2 and IRAK3 are classified as pseudokinases. IRAK2 is a positive regulator of NF- κ B pro-inflammatory signalling by promoting TRAF6 polyubiquitylation [106–108], and mutations within the pseudokinase domain can either enhance or suppress the magnitude of this signalling response [109–111]. IRAK3 binds to and antagonises other IRAK family members, acting as a switch to initiate suppression of the inflammatory response through MEKK3 driven NF- κ B signalling [112–114]. Also involved in TGF- β signalling is pseudopodium enriched atypical kinase 1 (PEAK1/SgK269), which enables a switch from canonical SMAD2/3 signalling to non-canonical Src-MAPK signalling pathways [115]. In addition, SgK269 acts as a scaffold between Src and ERBB2/HER2, enabling the Src-dependent phosphorylation of ERBB2/HER2 thereby promoting its activation [116].

Integrin linked kinase (ILK), whose primary role is as a scaffold to recruit key proteins involved in integrin function and dynamics [117,118], is also important for enabling the activation of other key signalling kinases, including GSK3, protein kinase B (PKB/AKT), and ERK1/2 [119–121]. Some of these interactions were proposed to involve catalytic activity of ILK, however structural, biochemical, and genetic studies indicate ILK is unlikely to possess catalytic activity, with mutations originally used to validate ILK kinase activity likely to affect protein stability [121–123]. Another pseudokinase is nuclear receptor binding protein 1 (NRBP1), an adapter protein that contains a putative Src homology 2 (SH2), nuclear receptor binding, nuclear import and export sequences [124]. The most well documented role of NRBP1 as a negative regulator downstream of Wnt-Ras signalling, where it is believed to act as a scaffold for ubiquitin ligase complex assembly [125,126]. Although little is known about the related pseudokinase NRBP2, recent data suggests a role in PKB/AKT signalling through an interaction with annexin A2 [127].

In the nucleus, we find the Tribbles pseudokinase (TRIB) family (**Figure 3**). TRIB2 has been shown to exhibit some catalytic activity in the absence of cations [128], however, like NRBP1, these pseudokinases are primarily adapter proteins which mediate a range of different intracellular functions [129]. Firstly, they bind to other kinases through their pseudokinase domain, such as members of the MAPKK family and PKB/AKT, modulating their phosphorylation and activation [130–132], with these interactions occurring in both cytoplasmic and nuclear compartments [133]. Secondly, they act as scaffolds to bring together various transcription factors, co-activators, and cell cycle modulators with E3 ligases such as COP-1, thus acting as regulators of transcription and cell cycle control [134–139]. Serine/threonine kinase 40 (STK40/SgK495), which is distantly related to the Tribbles proteins, has also been shown to interact with COP-1 [140]. Furthermore, it has been implicated in the regulation of various transcription factors, has a predominantly nuclear localisation and, more recently, has been implicated in the regulation of HDACs [141–143].

In addition to the Tribbles proteins, there are a number of other pseudokinases that spend most of their time in the nuclear compartment, either involved in cell cycle control or transcriptional control (**Figure 3**). BUBR1/BUB1B is an important component of the mitotic checkpoint complex, and also modulates the activity of the APC/C^{Cdc20} ubiquitylation complex [144–148]. In addition to acting as a scaffold between multiple proteins in these complexes, BUBR1 also acts as a mechanosensor between kinetochores and microtubules [149,150], a function that would be tempting to attribute to the dynamic properties of the kinase-like domain. Both testis expressed 14 (TEX14/SgK307) and serine/threonine kinase 31 (STK31/SgK396) are also involved in cell cycle control [151,152], and although it is known that TEX14 binds to, and likely sequesters, centrosomal protein 55 (CEP55) [153,154], the mechanism behind the actions of STK31 are not well defined. Finally, rounding out the nuclear pseudokinases is transformation/transcription domain associated protein (TRRAP), which is a very large and important scaffold protein for histone acetyltransferase complexes [155–159].

At the cell surface, there are a group of pseudokinases involved in control of cilia and flagella function (**Figure 4**). The NME/NM23 family members (NMEs) do not contain conventional protein kinase domains, but contain one or more nucleoside diphosphate kinase (NDPK) domains (reviewed in [160]). The primary role of NDPKs is in replenishment of nucleoside triphosphates, however this domain also possesses histidine kinase activity (reviewed in [161]). The human NME/NM23 family includes three proteins with pseudo-NDPK domains: NME5, NME7, and NME8 (reviewed in [162]). NME7 contains two NDPK domains, and although domain A has been shown to be catalytically active, domain B does not have detectable phosphotransfer activity [163]. NME7 is associated with cilia, and has an important role in microtubule organisation and nucleation through mediating interactions in the gamma tubulin ring complex, where the pseudokinase domain

is essential for binding of NME7 to this complex [163,164]. NME5 and NME8 are both highly expressed in the testes [165,166], and although the specific functions of NME5 are not well known, NME8, which contains three NDPK domains, is believed to form part of the outer dynein arm in flagellum and cilium [167,168], and defects in this gene are associated with primary ciliary dyskinesia [169]. Additionally, NME8 is implicated in protection against oxidative stress in spermatozoa [170], presumably through its thioredoxin domain, which exhibits increased activity when expressed without the pseudokinase domains [166]. Finally, there are two pseudokinases associated with specialist cilia: retinitis pigmentosa 2 (RP2), which also contains an NDPK domain and is important for regulating the length of photoreceptor sensory cilia [171–173], and unc-51 like kinase 4 (ULK4), which plays an important scaffolding role for the cilia involved in the circulation of cerebrospinal fluid (CSF) [174]. Both of these pseudokinases have additional roles in regulating the activity of GTPases that modulate assembly of larger protein complexes [175,176] (**Figure 4**).

Another subgroup of pseudokinases comprise those associated with intracellular trafficking (**Figure 4**), including the SCY1 like pseudokinase (SCYLs) [177]. Although the mechanisms involved in SCYL3 mediated transport are unclear [178], both SCYL1 and SCYL2 are known to play a scaffolding role in vesicle formation, with SCYL1 involved in formation of COPI coated vesicles important in Golgi to ER retrograde transport [179,180], and SCYL2 being associated with the clathrin coated vesicles involved receptor mediated endocytosis [181–183]. CaM kinase like vesicle associated (CAMKV/VACAMKL) is a vesicle associated pseudokinase, which until recently had no known function, however a recent study shows it to be a substrate of Cdk5 and is important for regulation of Rho GTPases at synapses through binding of the guanine nucleotide exchange factor Lcf [184]. Associated with early endosomes by virtue of a PX domain is the protein ribosomal protein S6 kinase C1 (RPS6KC1/RPK118/RSKL1), whose pseudokinase domain has been shown to bind a number of proteins and recruit them to the endosomal compartment [185,186]. PX domain containing serine/threonine kinase like (PXX/Slob) is another pseudokinase associated with receptor internalisation, and is believed to bind membranes at the C-terminal and actin at the N-terminal [187,188]. The mechanism behind PXX's function is not well defined, however it is tempting to speculate that the pseudokinase domain may act as a mechanical switch to facilitate movement of receptor complexes inside the cell. To round out the intracellular traffickers there are the less well known chromosome X open reading frame 36 (CXorf36/DIA1R), which has been proposed to localise to secretory compartments [189], and FJX1, a secretory protein belonging to the newly categorised FAM20 kinase family, which is implicated in dendrite elongation [190].

Finally, there are pseudokinases that participate in intracellular signalling hubs predominantly in the cytoplasm (**Figure 3**). This includes the giant polypeptide titin (TTN), whose best-known role is as a member of muscle fibre sarcomeres. The N-terminal kinase-like domain of TTN interacts with the ZFN protein Nrb1, and mutations within the pseudokinase domain that interrupt this interaction are linked to hereditary muscle disease [191]. The TTN pseudokinase domain also recruits the E3 ligases Murf1 and Murf2 [191,192], and is also proposed to act as a mechanosensor, similar to BUBR1 [193]. Ribonuclease L (RNaseL) is a protein whose primary function is to cleave ssRNA through its C-terminal RNase domain, whose activity relies on dimerization and essential cofactor binding by the central pseudokinase domain and N-terminal Ankyrin repeat domain [194–197]. Also in this group is PEAK1 related kinase activating pseudokinase 1 (PRAG1/SgK223), which assembles into heteromeric complexes with PEAK1/SgK169 [198], and binds to and sequesters the Src family inhibitory kinase Csk in the cytoplasm to potentiate Src activation [199]. In addition, PRAG1/SgK223 promotes Rho GTPase activity, which is enhanced by the binding of the GTPase Rnd2 to the PRAG1/SgK223 pseudokinase domain [200]. Last, but not least, is the pseudokinase mixed lineage kinase domain-like (MLKL), which acts as the most downstream known effector in the necroptotic cell death pathway [201,202]. The killer domain of MLKL is its N-terminal four

helical bundle (4HB) domain, however in the absence of upstream stimuli, this domain is proposed to be held in check by interactions with the C-terminal pseudokinase domain [203,204]. The pseudokinase domain serves as a receiver of an upstream signal in the form of phosphorylation by RIPK3, whereupon MLKL leaves the cytoplasmic compartment and translocates to membranes to initiate cell death by an unclear mechanism.

Conclusions

Based on known functions in allosteric enzyme regulation, regulation of cellular localisation/trafficking and as hubs for the assembly of signalling complexes, we have sought to functionally categorize pseudokinases. Much remains to be learned about additional functions of pseudokinases in signalling and the prevalence of pseudokinases serving a combination of these functions. For example, one of the best characterised pseudokinases, MLKL, is illustrative of the functional pleiotropy that can be served by pseudokinase domains, because this domain acts as a molecular switch [203], a suppressor of the 4HB executioner domain [204], and a protein interaction domain to recruit downstream effectors [205], such as the co-chaperones Cdc37-HSP90 [206]. It remains of enormous interest to determine whether regulation of the MLKL 4HB domain by its adjacent pseudokinase domain is illustrative of more widespread phenomena where pseudoenzyme domains have evolved functions as regulators of neighbouring domains *in cis*. This theme is evident among the tandem pseudokinase-kinase domains of the JAK family and GCN2, in addition to the tandem pseudokinase-guanylate kinase domains of the RGC family. While we have a detailed understanding of a subset of pseudokinase domain-containing proteins, there are five pseudokinases that are yet to be ascribed functions that we have been unable to categorise based on our present understanding. Ribosomal protein S6 kinase like 1 (RPS6KL1), which is related to RPS6KC1, but lacks the phosphoinositide domain and thus any likely membrane localisation, has been proposed as important for cell survival in two separate RNAi studies, but the underlying mechanism is unknown [207,208]. The pseudokinase serine/threonine kinase like domain containing 1 (SgK071/STKLD1) has been identified as a strong candidate in screening studies for involvement in tamoxifen resistance and influenza virus replication [209,210], but its function remains enigmatic. TBC1 domain containing kinase (TBCK) has been implicated in mTOR signalling and, besides possessing a putative GTPase activating domain, there is little known about its mechanism of action [211]. Selenoprotein O (SELENOO/SELO) is a mitochondrial selenoprotein with a possible role in chondrocyte differentiation and proliferation [212–214], although the role of SELO's pseudokinase domain is currently unclear. Finally, protein serine kinase H2 (PSKH2) is a pseudokinase of unknown function that has been lost from the mouse and rat kinomes, and is the counterpart of the conventional kinase, PSKH1 [215]. Detailed mechanistic and biological studies will play an important role in deducing the precise functions of these poorly-understood pseudokinases and will almost certainly reveal unexpected functions of others. We also expect that future studies will illuminate the extent to which the diverse signalling functions of pseudokinases provide a window into the non-catalytic mechanisms mediated by conventional protein kinases.

Acknowledgements

We thank our colleagues in the field, including those at the Pseudoenzymes focused meeting in Liverpool, for stimulating discussions. We apologize to those whose work we were unable to cite due to space considerations.

Funding

AVJ is supported by an Australian Government Research Training Program Scholarship and JMM by a National Health and Medical Research Council of Australia (NHMRC) fellowship (1105754). Our work reviewed herein was supported by NHMRC Project grants (1057905, 1067289, 1124735 and 1124737), NHMRC IRIISS 9000220 and Victorian Government Operational Infrastructure Support.

References

1. Evers PA, Murphy JM. The evolving world of pseudoenzymes: proteins, prejudice and zombies. *BMC Biol.* 2016;14(1):98.
2. Murphy JM, Farhan H, Evers P. Bio zombie: the rise of pseudoenzymes in biology. *Biochem Soc Trans.* 2017;(In Press).
3. Evers PA, Murphy JM. Dawn of the dead: protein pseudokinases signal new adventures in cell biology. *Biochem Soc Trans.* 2013;41(4):969–74.
4. Bailey FP, Byrne DP, McSkimming D, Kannan N, Evers P a. Going for broke: targeting the human cancer pseudokinome. *Biochem J.* 2015;465(2):195–211.
5. Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. *Science.* 1988;241(1985):42–52.
6. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. *Science.* 2002;298(5600):1912–34.
7. Zheng J, Knighton DR, Ten Eyck LF, Karlsson R, Xuong N, Taylor SS, et al. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. *Biochemistry.* 1993;32(9):2154–61.
8. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. Emerging roles of pseudokinases. *Trends Cell Biol.* 2006;16(9):443–52.
9. Murphy JM, Zhang Q, Young SN, Reese ML, Bailey FP, Evers PA, et al. A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. *Biochem J.* 2014;457(2):323–34.
10. Artim SC, Mendrola JM, Lemmon MA. Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family. *Biochem J.* 2012;448(2):213–20.
11. Kung JE, Jura N. Structural basis for the non-catalytic functions of protein kinases. *Structure.* 2016;24(1):7–24.
12. Taylor SS, Kornev AP. Protein kinases: Evolution of dynamic regulatory proteins. *Trends Biochem Sci.* 2011;36(2):65–77.
13. Scheeff ED, Eswaran J, Bunkoczi G, Knapp S, Manning G. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. *Structure.* 2009;17(1):128–38.
14. Kang T-H, Kim K-T. Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase. *Nat Cell Biol.* 2006;8(April):863–9.
15. Song H, Kim W, Choi J-H, Kim S-H, Lee D, Park C-H, et al. Stress-induced nuclear translocation of CDK5 suppresses neuronal death by downregulating ERK activation via VRK3 phosphorylation. *Sci Rep.* 2016;6(March):28634.
16. Wolf J, Valkov E, Allen MD, Meineke B, Gordiyenko Y, McLaughlin SH, et al. Structural basis for Pan3 binding to Pan2 and its function in mRNA recruitment and deadenylation. *EMBO J.* 2014;33(14):1514–26.
17. Schäfer IB, Rode M, Bonneau F, Schüssler S, Conti E. The structure of the Pan2-Pan3 core complex reveals cross-talk between deadenylase and pseudokinase. *Nat Struct Mol Biol.* 2014;21(7):591–8.
18. Jonas S, Christie M, Peter D, Bhandari D, Loh B, Huntzinger E, et al. An asymmetric PAN3

- dimer recruits a single PAN2 exonuclease to mediate mRNA deadenylation and decay. *Nat Struct Mol Biol.* 2014;21(7):599–608.
19. Christie M, Boland A, Huntzinger E, Weichenrieder O, Izaurralde E. Structure of the PAN3 pseudokinase reveals the basis for interactions with the PAN2 deadenylase and the GW182 proteins. *Mol Cell.* 2013;51(3):360–73.
 20. Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN. The molecular regulation of Janus kinase (JAK) activation. *Biochem J.* 2014;462(1):1–13.
 21. Ungureanu D, Wu J, Pekkala T, Niranjani Y, Young C, Jensen ON, et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signalling. *Nat Struct Mol Biol.* 2015;18(9):961–76.
 22. Lupardus PJ, Ultsch M, Wallweber H, Bir Kohli P, Johnson AR, Eigenbrot C. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. *Proc Natl Acad Sci U S A.* 2014;111(22):8025–30.
 23. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. *Mol Cell Biol.* 2000;20(10):3387–95.
 24. Chen M, Cheng A, Candotti F, Zhou YJ, Hymel A, Fasth A, et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. *Mol Cell Biol.* 2000;20(3):947–56.
 25. Wilks AF, Harpur AG, Kurban RR, Ralph SJ, Zürcher G, Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. *Mol Cell Biol.* 1991;11(4):2057–65.
 26. Velazquez L, Mogensen KE, Barbieri G, Fellous M, Uzéz G, Pelligrini S. Distinct domains of the protein tyrosin kinase tyk2 required for binding of interferon- α/β and for signal transduction. *J Biol Chem.* 1995;270(7):3327–34.
 27. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. *J Biol Chem.* 2002;277(49):47954–63.
 28. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. *Oncogene.* 2012;32(May):1–13.
 29. O’Shea JJ, Schwartz DM, Villarino A V., Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. *Annu Rev Med.* 2015;66(1):311–28.
 30. Varghese LN, Ungureanu D, Liao NPD, Young SN, Laktyushin A, Hammaren H, et al. Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. *Biochem J.* 2014;458(2):395–405.
 31. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. *Nature.* 2012;489(7414):155–9.
 32. Brooks AJ, Dai W, O’Mara M, Abankwa D, Chhabra Y, Pelekanos RA, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. *Science.* 2014;344(6185):1279783.
 33. Castilho BA, Shanmugam R, Silva RC, Ramesh R, Himme BM, Sattlegger E. Keeping the eIF2 alpha kinase Gcn2 in check. *Biochim Biophys Acta - Mol Cell Res.* 2014;1843(9):1948–68.
 34. Lageix S, Rothenburg S, Dever TE, Hinnebusch AG. Enhanced interaction between pseudokinase and kinase Domains in Gcn2 stimulates eIF2 α phosphorylation in starved cells. *PLoS Genet.* 2014;10(5):e1004326.
 35. Baas AF, Boudeau J, Sapkota GP, Smit L, Medema R, Morrice NA, et al. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. *EMBO J.*

- 2003;22(12):3062–72.
36. Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M, et al. MO25 α/β interact with STRAD α/β enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. *EMBO J.* 2003;22(19):5102–14.
 37. Veleva-Rotse BO, Smart JL, Baas AF, Edmonds B, Zhao Z-M, Brown A, et al. STRAD pseudokinases regulate axogenesis and LKB1 stability. *Neural Dev.* 2014;9(1):5.
 38. Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DMF. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. *Science.* 2009;326(5960):1707–11.
 39. Mukherjee K, Sharma M, Urlaub H, Bourenkov GP, Jahn R, Südhof TC, et al. CASK Functions as a Mg²⁺-Independent Neurexin Kinase. *Cell.* 2008;133(2):328–39.
 40. Lu CS, Hodge JLL, Mehren J, Sun XX, Griffith LC. Regulation of the Ca²⁺/CaM-responsive pool of CaMKII by scaffold-dependent autophosphorylation. *Neuron.* 2003;40(6):1185–97.
 41. Gillespie JM, Hodge JLL. CASK regulates CaMKII autophosphorylation in neuronal growth, calcium signaling, and learning. *Front Mol Neurosci.* 2013;6(September):27.
 42. Hodge JLL, Mullasseril P, Griffith LC. Activity-dependent gating of CaMKII autonomous activity by *Drosophila* CASK. *Neuron.* 2006;51(3):327–37.
 43. Cui J, Xiao J, Tagliabracci VS, Wen J, Rahdar M, Dixon JE. A secretory kinase complex regulates extracellular protein phosphorylation. *Elife.* 2015;4(4):e06120.
 44. Tagliabracci VS, Pinna LA, Dixon JE. Secreted protein kinases. *Trends Biochem Sci.* 2013;38(3):121–30.
 45. Ohyama Y, Lin J-H, Govitvattana N, Lin I-P, Venkitapathi S, Alamoudi A, et al. FAM20A binds to and regulates FAM20C localization. *Sci Rep.* 2016;6(April):srep27784.
 46. Kuhn M. Molecular Physiology of Membrane Guanylyl Cyclase Receptors. *Physiol Rev.* 2016;96(2):751–804.
 47. Biswas KH, Shenoy AR, Dutta A, Visweswariah SS. The evolution of guanylyl cyclases as multidomain proteins: Conserved features of kinase–cyclase domain fusions. *J Mol Evol.* 2009;68(6):587–602.
 48. Duda T, Yadav P, Sharma RK. ATP allosteric activation of atrial natriuretic factor receptor guanylate cyclase. *FEBS J.* 2010;277(11):2550–63.
 49. Jaleel M, Saha S, Shenoy AR, Visweswariah SS. The kinase homology domain of receptor guanylyl cyclase C: ATP binding and identification of an adenine nucleotide sensitive site. *Biochemistry.* 2006;45(6):1888–98.
 50. Yamazaki M, Usukura J, Yamazaki RK, Yamazaki A. ATP binding is required for physiological activation of retinal guanylate cyclase. *Biochem Biophys Res Commun.* 2005;338(2):1291–8.
 51. Yamazaki A, Yu H, Yamazaki M, Honkawa H, Matsuura I, Usukura J, et al. A critical role for ATP in the stimulation of retinal guanylyl cyclase by guanylyl cyclase-activating proteins. *J Biol Chem.* 2003;278(35):33150–60.
 52. Oliver PM, Fox JE, Kim R, Rockman H a, Kim HS, Reddick RL, et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. *Proc Natl Acad Sci U S A.* 1997;94(December):14730–5.
 53. Chang MS, Lowe DG, Lewis M, Hellmiss R, Chen E, Goeddel D V. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. *Nature.* 1989;341(6237):68–72.
 54. Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y, Potter LR. Differential regulation of membrane guanylyl cyclases in congestive heart failure: Natriuretic peptide receptor (NPR)-B, not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. *Endocrinology.* 2007;148(7):3518–22.
 55. Basu N, Arshad N, Visweswariah SS. Receptor guanylyl cyclase C (GC-C): Regulation and

- signal transduction. *Mol Cell Biochem.* 2010;334(1–2):67–80.
56. Laura RP, Hurley JB. The kinase homology domain of retinal guanylyl cyclases 1 and 2 specifies the affinity and cooperativity of interaction with guanylyl cyclase activating protein-2. *Biochemistry.* 1998;37(32):11264–71.
 57. Krylov DM, Hurley JB. Identification of Proximate Regions in a Complex of Retinal Guanylyl Cyclase 1 and Guanylyl Cyclase-activating Protein-1 by a Novel Mass Spectrometry-based Method. *J Biol Chem.* 2001;276(33):30648–54.
 58. Peshenko I V., Olshevskaya E V., Dizhoor AM. Evaluating the role of retinal membrane guanylyl cyclase 1 (RetGC1) domains in binding guanylyl cyclase-activating proteins (GCAPs). *J Biol Chem.* 2015;290(11):6913–24.
 59. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. *Proc Natl Acad Sci U S A.* 2008;105(8):3047–52.
 60. Liu Y, Rubin B, Bodine PVN, Billiard J. Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. *J Cell Biochem.* 2008;105(2):497–502.
 61. Billiard J, Way DS, Seestaller-Wehr LM, Moran R a, Mangine A, Bodine PVN. The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. *Mol Endocrinol.* 2005;19(1):90–101.
 62. Grumolato L, Liu G, Mong P, Mudbhary R, Biswas R, Arroyave R, et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. *Genes Dev.* 2010;24:2517–30.
 63. Bainbridge TW, DeAlmeida VI, Izrael-Tomasevic A, Chalouni C, Pan B, Goldsmith J, et al. Evolutionary divergence in the catalytic activity of the CAM-1, ROR1 and ROR2 kinase domains. *PLoS One.* 2014;9(7).
 64. Li C, Chen H, Hu L, Xing Y, Sasaki T, Villosis MF, et al. Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. *BMC Mol Biol.* 2008;9:11.
 65. Yu J, Chen L, Cui B, Widhopf GF, Shen Z, Wu R, et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. *J Clin Invest.* 2016;126(2):585–98.
 66. Yamaguchi T, Lu C, Ida L, Yanagisawa K, Usukura J, Cheng J, et al. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. *Nat Commun.* 2015;7:1–13.
 67. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. Ror1 is a pseudokinase that is crucial for met-driven tumorigenesis. *Cancer Res.* 2011;71(8):3132–41.
 68. Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, et al. NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma. *Cancer Cell.* 2012;21(3):348–61.
 69. Li C, Xiao J, Hormi K, Borok Z, Minoo P. Wnt5a participates in distal lung morphogenesis. *Dev Biol.* 2002;248(1):68–81.
 70. Blakely BD, Bye CR, Fernando C V, Prasad AA, Pasterkamp RJ, Macheda ML, et al. Ryk, a receptor regulating Wnt5a-mediated neurogenesis and axon morphogenesis of ventral midbrain dopaminergic neurons. *Stem Cells Dev.* 2013;22(15):2132–44.
 71. Halford MM, Armes J, Buchert M, Meskenaitė V, Grail D, Hibbs ML, et al. Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk. *Nat Genet.* 2000;25(august 2000):414–8.
 72. Yamaguchi TP, Bradley A, McMahon AP, Jones S. A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. *Development.* 1999;126(6):1211–23.
 73. Lu W, Yamamoto V, Ortega B, Baltimore D. Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth. *Cell.* 2004;119(1):97–108.
 74. Zhong J, Kim H-T, Lyu J, Yoshikawa K, Nakafuku M, Lu W. The Wnt receptor Ryk

- controls specification of GABAergic neurons versus oligodendrocytes during telencephalon development. *Development*. 2011;138(3):409–19.
75. Peradziryi H, Kaplan NA, Podleschny M, Liu X, Wehner P, Borchers A, et al. PTK7/Otk interacts with Wnts and inhibits canonical Wnt signalling. *EMBO J*. 2011;30(18):3729–40.
76. Wehner P, Shnitsar I, Urlaub H, Borchers A. RACK1 is a novel interaction partner of PTK7 that is required for neural tube closure. *Development*. 2011;138(7):1321–7.
77. Shnitsar I, Borchers A. PTK7 recruits dsh to regulate neural crest migration. *Development*. 2008;135(24):4015–24.
78. Puppo F, Thomé V, Lhoumeau A-C, Cibois M, Gangar A, Lembo F, et al. Protein tyrosine kinase 7 has a conserved role in Wnt/ β -catenin canonical signalling. *EMBO Rep*. 2011;12(1):43–9.
79. Li J, Wu F, Sheng F, Li YJ, Jin D, Ding X, et al. NOK/STYK1 interacts with GSK-3 β and mediates Ser9 phosphorylation through activated Akt. *FEBS Lett*. 2012;586(21):3787–92.
80. Li YH, Wang YY, Zhong S, Rong ZL, Ren YM, Li ZY, et al. Transmembrane helix of novel oncogene with kinase-domain (NOK) influences its oligomerization and limits the activation of RAS/MAPK signaling. *Mol Cells*. 2009;27(1):39–45.
81. Carraway KL, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, et al. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. *Nature*. 1997;387:512–6.
82. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. *Proc Natl Acad Sci U S A*. 2003;100(15):8933–8.
83. Tao R-H, Maruyama IN. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. *J Cell Sci*. 2008;121(Pt 19):3207–17.
84. Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. *Sci Signal*. 2015;7(354):ra114.
85. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. *Proc Natl Acad Sci U S A*. 2009;106(51):21608–13.
86. Monsey J, Shen W, Schlesinger P, Bose R. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. *J Biol Chem*. 2010;285(10):7035–44.
87. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. *Proc Natl Acad Sci U S A*. 2010;107(17):7692–7.
88. Mendrola JM, Shi F, Park JH, Lemmon MA. Receptor tyrosine kinases with intracellular pseudokinase domains. *Biochem Soc Trans*. 2013;41(4):1029–36.
89. Truitt L, Freywald T, DeCoteau J, Sharfe N, Freywald A. The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells. *Cancer Res*. 2010;70(3):1141–53.
90. Freywald A, Sharfe N, Roifman CM. The kinase-null EphB6 receptor undergoes transphosphorylation in a complex with EphB1. *J Biol Chem*. 2002;277(6):3823–8.
91. Freywald A, Sharfe N, Rashotte C, Grunberger T, Roifman CM. The EphB6 receptor inhibits JNK activation in T lymphocytes and modulates T cell receptor-mediated responses. *J Biol Chem*. 2003;278(12):10150–6.
92. Matsuoka H, Obama H, Kelly ML, Matsui T, Nakamoto M. Biphasic functions of the kinase-defective Ephb6 receptor in cell adhesion and migration. *J Biol Chem*. 2005;280(32):29355–63.
93. Roy F, Therrien M. MAP kinase module: The Ksr connection. *Curr Biol*. 2002;12(9):325–7.
94. Lin J, Harding A, Giurisato E, Shaw AS. KSR1 modulates the sensitivity of mitogen-activated protein kinase pathway activation in T cells without altering fundamental system outputs. *Mol Cell Biol*. 2009;29(8):2082–91.

95. Kolesnick R, Xing HR. Inflammatory bowel disease reveals the kinase activity of KSR1. *J Clin Invest.* 2004;114(9):1233–7.
96. Zhang H, Koo CY, Stebbing J, Giamas G. The dual function of KSR1 : a pseudokinase and beyond. *Biochem Soc Trans.* 2013;41(4):1078–82.
97. Brennan DF, Dar AC, Hertz NT, Chao WCH, Burlingame AL, Shokat KM, et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. *Nature.* 2011;472(7343):366–9.
98. Chen C, Lewis RE, White MA. IMP modulates KSR1-dependent multivalent complex formation to specify ERK1/2 pathway activation and response thresholds. *J Biol Chem.* 2008;283(19):12789–96.
99. Jagemann LR, Pérez-Rivas LG, Ruiz EJ, Ranea JA, Sánchez-Jiménez F, Nebreda ÁR, et al. The functional interaction of 14-3-3 proteins with the ERK1/2 scaffold KSR1 occurs in an isoform-specific manner. *J Biol Chem.* 2008;283(25):17450–62.
100. Channavajhala PL, Rao VR, Spaulding V, Lin L, Zhang YG. hKSR-2 inhibits MEKK3-activated MAP kinase and NF- κ B pathways in inflammation. *Biochem Biophys Res Commun.* 2005;334:1214–8.
101. Rajakulendran T, Sahmi M, Lefrançois M, Sicheri F, Therrien M. A dimerization-dependent mechanism drives RAF catalytic activation. *Nature [Internet].* 2009;461(7263):542–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19727074>
102. Hu J, Stites EC, Yu H, Germino EA, Meharena HS, Stork PJS, et al. Allosteric activation of functionally asymmetric RAF kinase dimers. *Cell [Internet].* 2013;154(5):1036–46. Available from: <http://dx.doi.org/10.1016/j.cell.2013.07.046>
103. Liu L, Channavajhala PL, Rao VR, Moutsatsos I, Wu L, Zhang Y, et al. Proteomic characterization of the dynamic KSR-2 interactome, a signaling scaffold complex in MAPK pathway. *Biochim Biophys Acta - Proteins Proteomics.* 2009;1794(10):1485–95.
104. Stewart S, Sundaram M, Zhang Y, Lee J, Han M, Guan KL. Kinase suppressor of Ras forms a multiprotein signaling complex and modulates MEK localization. *Mol Cell Biol.* 1999;19(8):5523–34.
105. Flannery S, Bowie AG. The interleukin-1 receptor-associated kinases: Critical regulators of innate immune signalling. *Biochem Pharmacol.* 2010;80(12):1981–91.
106. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. *Science.* 1997;278(5343):1612–5.
107. Keating SE, Maloney GM, Moran EM, Bowie AG. IRAK-2 participates in multiple Toll-like receptor signaling pathways to NF κ B via activation of TRAF6 ubiquitination. *J Biol Chem.* 2007;282(46):33435–43.
108. Guo F, Wu S. IRAK-2 and PI 3-kinase synergistically activate NF- κ B and AP-1. *Inflammation.* 2000;24(4):305–16.
109. Wang H, El Maadidi S, Fischer J, Grabski E, Dickhöfer S, Klimosch S, et al. A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. *Hepatology.* 2015;62(5):1375–87.
110. Wang H, Flannery SM, Dickhof'er S, Huhn S, George J, Kubarenko A V., et al. A coding IRAK2 protein variant compromises toll-like receptor (TLR) signaling and is associated with colorectal cancer survival. *J Biol Chem.* 2014;289(33):23123–31.
111. Zhang W, He T, Wang Q, Li X, Wei J, Hou X, et al. Interleukin-1 receptor-associated kinase-2 genetic variant rs708035 increases NF- κ B activity through promoting TRAF6 ubiquitination. *J Biol Chem.* 2014;289(18):12507–19.
112. Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, Cao Z. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. *J Biol Chem.* 1999;274(27):19403–10.
113. Zhou H, Yu M, Fukuda K, Im J, Yao P, Cui W, et al. IRAK-M mediates Toll-like

- receptor/IL-1R-induced NF κ B activation and cytokine production. *EMBO J.* 2013;32(4):583–96.
114. Su J, Xie Q, Wilson I, Li L. Differential regulation and role of Interleukin-1 Receptor Associated Kinase-M in innate immunity signalling. *Cell Signal.* 2007;19(7):1596–601.
 115. Agajanian M, Campeau A, Hoover M, Hou A, Brambilla D, Kim S La, et al. PEAK1 acts as a molecular switch to regulate context-dependent TGF β responses in breast cancer. *PLoS One.* 2015;10(8):e0135748.
 116. Kelber JA, Reno T, Kaushal S, Metildi C, Wright T, Stoletov K, et al. KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. *Mol Cell Pathobiol.* 2012;72(10):2554–64.
 117. Fukuda K, Gupta S, Chen K, Wu C, Qin J. The pseudo-active site of ILK is essential for its binding to α -parvin and localization to focal adhesions. *Mol Cell.* 2009;36(5):819–30.
 118. Ghatak S, Morgner J, Wickstrom SA. ILK: a pseudokinase with a unique function in the integrin-actin linkage. *Biochem Soc Trans.* 2013;41(4):995–1001.
 119. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. *Proc Natl Acad Sci.* 1998;95(September):11211–6.
 120. Tseng P, Chen C, Shan Y, Chang W, Liu H, Hong T, et al. An increase in integrin-linked kinase non-canonically confers NF- κ B-mediated growth advantages to gastric cancer cells by activating ERK1/2. *Cell Commun Signal.* 2014;12:69.
 121. Lynch DK, Ellis CA, Edwards PAW, Hiles ID. Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. *Oncogene.* 1999;18:8024–32.
 122. Fukuda K, Knight JDR, Piszczek G, Kothary R, Qin J. Biochemical, proteomic, structural, and thermodynamic characterizations of integrin-linked kinase (ILK): Cross-validation of the pseudokinase. *J Biol Chem.* 2011;286(24):21886–95.
 123. Lange A, Wickström S a, Jakobson M, Zent R, Sainio K, Fässler R. Integrin-linked kinase is an adaptor with essential functions during mouse development. *Nature.* 2009;461(7266):1002–6.
 124. Kerr JS, Wilson CH. Nuclear receptor-binding protein 1: a novel tumour suppressor and pseudokinase. *Biochem Soc Trans.* 2013;41(4):1055–60.
 125. Wilson CH, Crombie C, Weyden L Van Der, Pouligiannis G, Rust AG, Pardo M, et al. Nuclear receptor binding protein 1 regulates intestinal progenitor cell homeostasis and tumour formation. *EMBO J.* 2012;31(11):2486–97.
 126. Wei H, Wang H, Ji Q, Sun J, Tao L, Zhou X. NRBP1 is downregulated in breast cancer and NRBP1 overexpression inhibits cancer cell proliferation through Wnt/ β -catenin signaling pathway. *Onco Targets Ther.* 2015;8:3721–30.
 127. Zhang L, Ge C, Zhao F, Zhang Y, Wang X, Yao M, et al. NRBP2 overexpression increases the chemosensitivity of hepatocellular carcinoma cells via Akt signaling. *Cancer Res.* 2016;76(23):7059–71.
 128. Bailey FP, Byrne DP, Oruganty K, Evers CE, Novotny CJ, Shokat KM, et al. The Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent manner. *Biochem J.* 2015;467(1):47–62.
 129. Evers PA, Keeshan K, Kannan N, Cohen P, Tcherpakov M, Hunter T, et al. Tribbles in the 21st Century: The evolving roles of Tribbles pseudokinases in biology and disease. *Trends Cell Biol.* 2016;(In Press).
 130. Kiss-Toth E, Bagstaff SM, Sung HY, Jozsa V, Dempsey C, Caunt JC, et al. Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. *J Biol Chem.* 2004;279(41):42703–8.
 131. Yokoyama T, Kanno Y, Yamazaki Y, Takahara T, Miyata S, Nakamura T. Trib1 links the

- MEK1/ERK pathway in myeloid leukemogenesis. *Blood*. 2010;116(15):2768–75.
132. Salazar M, Lorente M, García-Taboada E, Pérez Gómez E, Dávila D, Zúñiga-García P, et al. Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation. *Cell Death Differ*. 2015;22(1):131–44.
 133. Guan H, Shuaib A, Leon DD De, Angyal A, Salazar M, Velasco G, et al. Competition between members of the tribbles pseudokinase protein family shapes their interactions with mitogen activated protein kinase pathways. *Sci Rep [Internet]*. 2016;6:srep32667. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27600771>
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5013389>
<http://www.nature.com/articles/srep32667>
 134. Jousse C, Deval C, Maurin AC, Parry L, Chérasse Y, Chaveroux C, et al. TRB3 inhibits the transcriptional activation of stress-regulated genes by a negative feedback on the ATF4 pathway. *J Biol Chem*. 2007;282(21):15851–61.
 135. Murphy JM, Nakatani Y, Jamieson SA, Dai W, Lucet IS, Mace PD. Molecular Mechanism of CCAAT-Enhancer Binding Protein Recruitment by the TRIB1 Pseudokinase. *Structure*. 2015;23(11):2111–21.
 136. Keeshan K, Bailis W, Dedhia PH, Vega ME, Shestova O, Xu L, et al. Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding. *Blood*. 2010;116(23):4948–57.
 137. Xu S, Tong M, Huang J, Zhang Y, Qiao Y, Weng W, et al. TRIB2 inhibits Wnt/ β -Catenin/TCF4 signaling through its associated ubiquitin E3 ligases, β -TrCP, COP1 and Smurf1, in liver cancer cells. *FEBS Lett*. 2014;588(23):4334–41.
 138. Keeshan K, He Y, Wouters BJ, Shestova O, Xu L, Sai H, et al. Tribbles homolog 2(Trib2) inactivates C/EBP α and causes acute myelogenous leukemia. *Cancer Cell*. 2006;10(5):410–1.
 139. Liang KL, Paredes R, Carmody R, Eyers PA, Meyer S, McCarthy T V., et al. Human TRIB2 oscillates during the cell cycle and promotes ubiquitination and degradation of CDC25C. *Int J Mol Sci*. 2016;17(9):1–13.
 140. Durzynska I, Xu X, Adelmant G, Ficarro SB, Marto JA, Sliz P, et al. STK40 Is a pseudokinase that binds the E3 ubiquitin ligase COP1. *Structure*. 2017;25(2):287–94.
 141. Yu H, He K, Wang L, Hu J, Gu J, Zhou C, et al. Stk40 represses adipogenesis through translational control of CCAAT/enhancer-binding proteins. *J Cell Sci*. 2015;128:2881–90.
 142. He K, Hu J, Yu H, Wang L, Tang F, Gu J, et al. Serine/Threonine Kinase 40 (Stk40) functions as a novel regulator of skeletal muscle differentiation. *J Biol Chem*. 2017;292(1):351–60.
 143. Huang J, Teng L, Liu T, Li L, Chen D, Li F, et al. Identification of a novel serine/threonine kinase that inhibits TNF-induced NF- κ B activation and p53-induced transcription. *Biochem Biophys Res Commun*. 2003;309(4):774–8.
 144. Kim HS, Jeon YK, Ha GH, Park HY, Kim YJ, Shin HJ, et al. Functional interaction between BubR1 and securin in an anaphase-promoting complex/cyclosomeCdc20-independent manner. *Cancer Res*. 2009;69(1):27–36.
 145. Kruse T, Zhang G, Larsen MSY, Lischetti T, Streicher W, Kragh Nielsen T, et al. Direct binding between BubR1 and B56-PP2A phosphatase complexes regulate mitotic progression. *J Cell Sci*. 2013;126(Pt 5):1086–92.
 146. Wang J, Wang Z, Yu T, Yang H, Virshup DM, Kops GJPL, et al. Crystal structure of a PP2A B56-BubR1 complex and its implications for PP2A substrate recruitment and localization. *Protein Cell*. 2016;7(7):516–26.
 147. Suijkerbuijk SJE, van Dam TJP, Karagöz GE, von Castelmur E, Hubner NC, Duarte AMS, et al. The vertebrate mitotic checkpoint protein BUBR1 is an unusual pseudokinase. *Dev Cell*. 2012;22(6):1321–9.

148. Yamaguchi M, VanderLinden R, Weissmann F, Qiao R, Dube P, Brown NG, et al. Cryo-EM of mitotic checkpoint complex-bound APC/C reveals reciprocal and conformational regulation of ubiquitin ligation. *Mol Cell*. 2016;63(4):593–607.
149. Huang H, Hittle J, Zappacosta F, Annan RS, Hershko A, Yen TJ. Phosphorylation sites in BubR1 that regulate kinetochore attachment, tension, and mitotic exit. *J Cell Biol*. 2008;183(4):667–80.
150. Chan GKT, Jablonski SA, Sudakin V, Hittle JC, Yen TJ. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. *J Cell Biol*. 1999;146(5):941–54.
151. Kuo PL, Huang YL, Hsieh CCJ, Lee JC, Lin BW, Hung LY. STK31 Is a cell-cycle regulated protein that contributes to the tumorigenicity of epithelial cancer cells. *PLoS One*. 2014;9(3):1–12.
152. Mondal G, Ohashi A, Yang L, Rowley M, Couch FJ. Tex14, a Plk1 regulated protein, is required for kinetochore- microtubule attachment and regulation of the spindle assembly checkpoint. *Mol Cell*. 2012;45(5):680–95.
153. Iwamori T, Iwamori N, Ma L, Edson MA, Greenbaum MP, Matzuk MM. TEX14 interacts with CEP55 to block cell abscission. *Mol Cell Biol*. 2010;30(9):2280–92.
154. Kim HJ, Yoon J, Matsuura A, Na J-H, Lee W-K, Kim H, et al. Structural and biochemical insights into the role of testis-expressed gene 14 (TEX14) in forming the stable intercellular bridges of germ cells. *Proc Natl Acad Sci*. 2015;14(40):201418606.
155. Li H, Cuenin C, Murr R, Wang Z-Q, Herceg Z. HAT cofactor Trrap regulates the mitotic checkpoint by modulation of Mad1 and Mad2 expression. *EMBO J*. 2004;23(24):4824–34.
156. McMahon SB, Wood MA, Cole MD. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. *Mol Cell Biol*. 2000;20(2):556–62.
157. Murr R, Loizou JI, Yang Y-G, Cuenin C, Li H, Wang Z-Q, et al. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. *Nat Cell Biol*. 2006;8(1):91–9.
158. Ichim G, Mola M, Finkbeiner M, Cros M-P, Herceg Z, Hernandez-Vargas H. The histone acetyltransferase component TRRAP is targeted for destruction during the cell cycle. *Oncogene*. 2014;33570(2):181–92.
159. Tapias A, Zhou ZW, Shi Y, Chong Z, Wang P, Groth M, et al. Trrap-dependent histone acetylation specifically regulates cell-cycle gene transcription to control neural progenitor fate decisions. *Cell Stem Cell*. 2014;14(5):632–43.
160. Četković H, Perina D, Harcet M, Mikoč A, Herak Bosnar M. Nme family of proteins - Clues from simple animals. *Naunyn Schmiedebergs Arch Pharmacol*. 2014;388(2):133–42.
161. Attwood P V, Wieland T. Nucleoside diphosphate kinase as protein histidine kinase. *Naunyn Schmiedebergs Arch Pharmacol*. 2015;388:153–60.
162. Lacombe M, Milon L, Munier A, Mehus JG, Lambeth DO. The Human Nm23 / Nucleoside Diphosphate Kinases. *J Bioenerg Biomembr*. 2000;32(3):247–58.
163. Liu P, Choi Y-K, Qi RZ. NME7 is a functional component of the γ -tubulin ring complex. *Mol Biol Cell*. 2014;25(13):2017–25.
164. Ikeda T. NDP kinase 7 is a conserved microtubule-binding protein preferentially expressed in ciliated cells. *Cell Struct Funct*. 2010;35(1):23–30.
165. Munier A, Feral C, Milon L, Pinon VPB, Gyapay G, Capeau J, et al. A new human nm23 homologue (nm23-H5) specifically expressed in testis germinal cells. *FEBS Lett*. 1998;434(3):289–94.
166. Sadek CM, Damdimopoulos AE, Pelto-Huikko M, Gustafsson JÅ, Spyrou G, Miranda-Vizuete A. Sptrx-2, a fusion protein composed of one thioredoxin and three tandemly repeated NDP-kinase domains is expressed in human testis germ cells. *Genes to Cells*. 2001;6(12):1077–90.

167. Pazour GJ, Agrin N, Walker BL, Witman GB. Identification of predicted human outer dynein arm genes: candidates for primary ciliary dyskinesia genes. *J Med Genet.* 2006;43(1):62–73.
168. Kobayashi D, Takeda H. Ciliary motility: The components and cytoplasmic preassembly mechanisms of the axonemal dyneins. *Differentiation.* 2012;83(2):S23–9.
169. Duriez B, Duquesnoy P, Escudier E, Bridoux A-M, Escalier D, Rayet I, et al. A common variant in combination with a nonsense mutation in a member of the thioredoxin family causes primary ciliary dyskinesia. *Proc Natl Acad Sci U S A.* 2007;104(9):3336–41.
170. Smith TB, Baker MA, Connaughton HS, Habenicht U, Aitken RJ. Functional deletion of *Txndc2* and *Txndc3* increases the susceptibility of spermatozoa to age-related oxidative stress. *Free Radic Biol Med.* 2013;65:872–81.
171. Chapple JP, Hardcastle AJ, Grayson C, Spackman LA, Willison KR, Cheetham ME. Mutations in the N-terminus of the X-linked retinitis pigmentosa protein RP2 interfere with the normal targeting of the protein to the plasma membrane. *Hum Mol Genet.* 2000;9(13):1919–26.
172. Kühnel K, Veltel S, Schlichting I, Wittinghofer A. Crystal structure of the human retinitis pigmentosa 2 protein and its interaction with Arl3. *Structure.* 2006;14(2):367–78.
173. Li L, Kollu NR, Zheng-Li Y, Hurd T, Lillo C, Khanna H. Loss of retinitis pigmentosa 2 (RP2) protein affects cone photoreceptor sensory cilium elongation in mice. *Cytoskeleton.* 2013;72(9):447–54.
174. Liu M, Guan Z, Shen Q, Lalor P, Fitzgerald U, O'Brien T, et al. *Ulk4* Is essential for ciliogenesis and CSF flow. *J Neurosci.* 2016;36(29):7589–600.
175. Veltel S, Gasper R, Eisenacher E, Wittinghofer A. The retinitis pigmentosa 2 gene product is a GTPase-activating protein for Arf-like 3. *Nat Struct Mol Biol.* 2008;15(4):373–80.
176. Tomoda T, Kim J, Zhan C, Hatten M. Role of *Unc51. 1* and its binding partners in CNS axon outgrowth. *Genes Dev.* 2004;18:541–58.
177. Pelletier S. SCYL pseudokinases in neuronal function and survival. *Neural Regen Res.* 2016;11(1):42–4.
178. Sullivan A, Uff CR, Isacke CM, Thorne RF. *PACE-1*, a novel protein that interacts with the C-terminal domain of ezrin. *Exp Cell Res.* 2003;284(2):224–38.
179. Hamlin JNR, Schroeder LK, Fotouhi M, Dokainish H, Ioannou MS, Girard M, et al. *Scyl1* scaffolds class II Arfs to specific subcomplexes of coatamer through the γ -COP appendage domain. *J Cell Sci.* 2014;127(Pt 7):1454–63.
180. Burman JL, Bourbonniere L, Philie J, Stroh T, Dejgaard SY, Presley JF, et al. *Scyl1*, mutated in a recessive form of spinocerebellar neurodegeneration, regulates COPI-mediated retrograde traffic. *J Biol Chem.* 2008;283(33):22774–86.
181. Borner GHH, Rana AA, Forster R, Harbour M, Smith JC, Robinson MS. *CVAK104* is a novel regulator of clathrin-mediated SNARE sorting. *Traffic.* 2007;8(7):893–903.
182. Terabayashi T, Funato Y, Fukuda M, Miki H. A coated vesicle-associated kinase of 104 kDa (*CVAK104*) induces lysosomal degradation of frizzled 5 (*Fzd5*). *J Biol Chem.* 2009;284(39):26716–24.
183. Düwel M, Ungewickell EJ. Clathrin-dependent association of *CVAK104* with endosomes and the trans-Golgi network. *Mol Biol Cell.* 2007;17:4513–25.
184. Liang Z, Zhan Y, Shen Y, Wong CCL, Yates JR, Plattner F, et al. The pseudokinase *CaMKv* is required for the activity-dependent maintenance of dendritic spines. *Nat Commun.* 2016;7:13282.
185. Liu L, Yang C, Yuan J, Chen X, Xu J, Wei Y, et al. *RPK118*, a PX domain-containing protein, interacts with peroxiredoxin-3 through pseudo-kinase domains. *Mol Cells.* 2005;19(1):39–45.
186. Hayashi S, Okada T, Igarashi N, Fujita T, Jahangeer S, Nakamura S ichi. Identification and characterization of *RPK118*, a novel sphingosine kinase-1-binding protein. *J Biol Chem.*

- 2002;277(36):33319–24.
187. Vaughn SE, Foley C, Shen N, Patel Z, Zoller E, Magnusen AF, et al. Lupus risk variants in the PXX locus alter B-cell receptor internalization. *Front Genet.* 2014;5(DEC):1–12.
 188. Takeuchi H, Takeuchi T, Gao J, Cantley LC, Hirata M. Characterization of PXX as a protein involved in epidermal growth factor receptor trafficking. *Mol Cell Biol.* 2010;30(7):1689–702.
 189. Aziz A, Harrop SP, Bishop NE. DIA1R is an X-linked gene related to Deleted In Autism-1. *PLoS One.* 2011;6(1).
 190. Probst B, Rock R, Gessler M, Vortkamp A, Püschel AW. The rodent Four-jointed ortholog Fjx1 regulates dendrite extension. *Dev Biol.* 2007;312(1):461–70.
 191. Lange S, Xiang F, Yakovenko A, Vihola A, Hackman P, Rostkova E, et al. The kinase domain of Titin controls muscle gene expression and protein turnover. *Science.* 2005;308(5728):1599–603.
 192. Bogomolovas J, Gasch A, Simkovic F, Rigden DJ, Labeit S, Mayans O. Titin kinase is an inactive pseudokinase scaffold that supports MuRF1 recruitment to the sarcomeric M-line. *Open Biol.* 2014;4(5):140041.
 193. Puchner EM, Alexandrovich A, Kho AL, Hensen U, Schafer L V., Brandmeier B, et al. Mechanoenzymatics of titin kinase. *Proc Natl Acad Sci.* 2008;105(36):13385–90.
 194. Han Y, Donovan J, Rath S, Whitney G, Chitrakar A, Korennykh A. Structure of human RNase L reveals the basis for regulated RNA decay in the IFN response. *Science.* 2014;343(6176):1244–8.
 195. Dong B, Silverman RH. Alternative function of a protein kinase homology domain in 2', 5'-oligoadenylate dependent RNase L. *Nucleic Acids Res.* 1999;27(2):439–45.
 196. Han Y, Whitney G, Donovan J, Korennykh A. Innate immune messenger 2-5A tethers human RNase L into active high-order complexes. *Cell Rep.* 2012;2(4):902–13.
 197. Huang H, Zeqiraj E, Dong B, Jha BK, Duffy NM, Orlicky S, et al. Dimeric structure of pseudokinase RNase L bound to 2-5A reveals a basis for interferon-induced antiviral activity. *Mol Cell.* 2014;53(2):221–34.
 198. Liu L, Phua YW, Lee RS, Ma X, Jenkins Y, Novy K, et al. Homo- and heterotypic association regulates signaling by the Sgk269/PEAK1 and Sgk223 pseudokinases. *J Biol Chem.* 2016;291(41):21571–83.
 199. Senda Y, Murata-Kamiya N, Hatakeyama M. C-terminal Src kinase-mediated EPIYA phosphorylation of Pragmin creates a feed-forward C-terminal Src kinase activation loop that promotes cell motility. *Cancer Sci.* 2016;107(7):972–80.
 200. Tanaka H, Katoh H, Negishi M. Pragmin, a novel effector of Rnd2 GTPase, Stimulates RhoA activity. *J Biol Chem.* 2006;281(15):10355–64.
 201. Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. *Cell.* 2012;148(1):213–27.
 202. Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. *Proc Natl Acad Sci.* 2012;109(14):5322–7.
 203. Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S, et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. *Immunity.* 2013;39(3):443–53.
 204. Hildebrand JM, Tanzer MC, Lucet IS, Young SN, Spall SK, Sharma P, et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. *Proc Natl Acad Sci.* 2014;111(42):15072–7.
 205. Tanzer MC, Matti I, Hildebrand JM, Young SN, Wardak A, Tripaydonis A, et al. Evolutionary divergence of the necroptosis effector MLKL. *Cell Death Differ.* 2016;23(7):1185–97.

206. Jacobsen A V., Lowes KN, Tanzer MC, Lucet IS, Hildebrand JM, Petrie EJ, et al. HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death. *Cell Death Dis.* 2016;7(1):e2051.
207. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. *Nat Cell Biol.* 2005;7(6):591–600.
208. Zumbansen M, Altrogge LM, Spottke NU, Spicker S, Offizier SM, Domzalski SB, et al. First siRNA library screening in hard-to-transfect HUVEC cells. *J RNAi Gene Silencing.* 2010;6(1):354–60.
209. Bakre A, Andersen LE, Meliopoulos V, Coleman K, Yan X, Brooks P, et al. Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs. *PLoS One.* 2013;8(6):e66796.
210. Gonzalez-Malerva L, Park J, Zou L, Hu Y, Moradpour Z, Pearlberg J, et al. High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. *Proc Natl Acad Sci.* 2011;108(5):2058–63.
211. Liu Y, Yan X, Zhou T. TBCK influences cell proliferation, cell size and mTOR signaling pathway. *PLoS One.* 2013;8(8):e71349.
212. Dudkiewicz M, Szczepinska T, Grynberg M, Pawłowski K. A novel protein kinase-like domain in a selenoprotein, widespread in the tree of life. *PLoS One.* 2012;7(2).
213. Han SJ, Lee BC, Yim SH, Gladyshev VN, Lee SR. Characterization of mammalian selenoprotein O: A redox-active mitochondrial protein. *PLoS One.* 2014;9(4).
214. Yan J, Fei Y, Han Y, Lu S. Selenoprotein O deficiencies suppress chondrogenic differentiation of ATDC5 cells. *Cell Biol Int.* 2016;40(10):1033–40.
215. Reiterer V, Eyers PA, Farhan H. Day of the dead: Pseudokinases and pseudophosphatases in physiology and disease. *Trends Cell Biol.* 2014;24(9):489–505.